Article(id=1322906817239592971, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322887806737825858, articleNumber=null, orderNo=null, doi=null, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=null, receivedDateStr=null, revisedDate=null, revisedDateStr=null, acceptedDate=1628524800000, acceptedDateStr=2021-08-10, onlineDate=1793335163649, onlineDateStr=2026-10-30, pubDate=1634227200000, pubDateStr=2021-10-15, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1793335163649, onlineIssueDateStr=2026-10-30, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1793335163649, creator=13701087609, updateTime=1793335163649, updator=13701087609, issue=Issue{id=1322887806737825858, tenantId=1146029695717560320, journalId=1235980733773295621, year='2021', volume='30', issue='19', pageStart='1729', pageEnd='1824', issueExtLink='null', onlineDate='null', pubDate='1634227200000', pubDateStr='2021-10-15', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1793330631192, creator='13701087609', updateTime=1793337389212, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1322916151994495727, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322887806737825858, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1322916151994495728, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322887806737825858, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1814, endPage=1818, ext={EN=ArticleExt(id=1322906819026366476, articleId=1322906817239592971, tenantId=1146029695717560320, journalId=1235980733773295621, language=EN, title=Progress in clinical study of intra-cavity administration of oncolytic virus, columnId=null, journalTitle=Chinese Journal of New Drugs, columnName=null, runingTitle=null, highlight=null, articleAbstract=

In recent years, increasing number of oncolytic virus drugs have entered clinical study. Administration approach mainly involves intratumoral, intravenous, intracranial intra-arberial, and so on. Among them, indications for intraperitoneal administration of oncolytic virus mostly include malignant pleural effusion, malignant pleural mesothelioma, and thoracic/abdominal cancer. Due to the inherent characteristics of the administration approach, the absorption of intra-cavity administration is slower than that by intravenous, and the pleural injection requires an indwelling catheter. The efficacy of intraperitoneal administration greatly varies among different oncolytic virus products and indications. Among them, pleural administration for malignant pleural effusion shows good efficacy, while the efficacy of intra-cavity administration for malignant pleural mesothelioma and ovarian cancer is unclear. Due to limited participants in relevant clinical study, the safety and efficacy need further verification by confirming clinical trials.

, authors=Xiao LIU, Yun-hong HUANG, Chen-yan GAO, authorsList=Xiao LIU, Yun-hong HUANG, Chen-yan GAO, authorCompany=null, correspAuthors=Yun-hong HUANG, Chen-yan GAO, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1322906819294801933, articleId=1322906817239592971, tenantId=1146029695717560320, journalId=1235980733773295621, language=CN, title=溶瘤病毒类药物腔内给药临床研究进展, columnId=1236331159400018080, journalTitle=中国新药杂志, columnName=新药注册与审评技术, runingTitle=null, highlight=null, articleAbstract=

近年来,越来越多的溶瘤病毒类药物进入临床研究,涉及给药方式主要有瘤内注射、静脉注射、腔内注射、颅内注射和动脉注射等。其中,腔内注射溶瘤病毒目标适应证多为恶性胸腹腔积液、恶性胸膜间皮瘤、胸腹腔部位的肿瘤,由于给药方式本身的特点,溶瘤病毒腔内给药的吸收速度比静脉注射慢,且胸腔注射需要置留管。腔内给药的疗效在不同的溶瘤病毒产品和适应证间差异较大,其中,胸腔注射治疗恶性胸腔积液显现出较好疗效,而腔内注射治疗间皮瘤、卵巢癌疗效尚不明确。由于相关临床研究入组人数均较少,安全性和有效性还需确证性临床试验进一步验证。

, authors=刘晓, 黄云虹, 高晨燕, authorsList=刘晓, 黄云虹, 高晨燕, authorCompany=null, correspAuthors=黄云虹, 高晨燕, authorNote=

刘晓,女,博士,主要从事生物制品临床审评工作。联系电话:(010)85243060,E-mail:。

, correspAuthorsNote=
黄云虹,女,博士,主要从事生物制品临床审评工作。联系电话:(010)85243080,E-mail:。
高晨燕,女,主任药师,主要从事生物制品临床审评工作。联系电话:(010)85243053,E-mail:。
, copyrightStatement=null, copyrightOwner=《中国新药杂志》有限公司, extLink=null, articleAbsUrl=null, sourceXml=oQoMareRe6RRA2AWYdtZZA==, magXml=BZ4b9IYZLms8Ru3daqxNIg==, pdfUrl=null, pdf=OcSdZSxFepDp6mEZsdXoOw==, pdfFileSize=865173, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=DnCZf45mjB6vkzDRJpIOmw==, mapNumber=null, fund=null)}, authors=[Author(id=1322906819596791826, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=liux@cde.org.cn, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322906819689066516, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, authorId=1322906819596791826, language=EN, stringName=Xiao LIU, firstName=Xiao, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322906819772952597, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, authorId=1322906819596791826, language=CN, stringName=刘晓, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=国家药品监督管理局药品审评中心,北京 100022, bio={"content":"

刘晓,女,博士,主要从事生物制品临床审评工作。联系电话:(010)85243060,E-mail:。

"}, bioImg=null, bioContent=

刘晓,女,博士,主要从事生物制品临床审评工作。联系电话:(010)85243060,E-mail:。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322906819491934222, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, xref=null, ext=[AuthorCompanyExt(id=1322906819504517135, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, companyId=1322906819491934222, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China), AuthorCompanyExt(id=1322906819512905744, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, companyId=1322906819491934222, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=国家药品监督管理局药品审评中心,北京 100022)])]), Author(id=1322906819852644375, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=huangyh@cde.org.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322906819949113369, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, authorId=1322906819852644375, language=EN, stringName=Yun-hong HUANG, firstName=Yun-hong, middleName=null, lastName=HUANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322906820045582362, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, authorId=1322906819852644375, language=CN, stringName=黄云虹, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=国家药品监督管理局药品审评中心,北京 100022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322906819491934222, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, xref=null, ext=[AuthorCompanyExt(id=1322906819504517135, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, companyId=1322906819491934222, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China), AuthorCompanyExt(id=1322906819512905744, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, companyId=1322906819491934222, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=国家药品监督管理局药品审评中心,北京 100022)])]), Author(id=1322906820121079836, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=gaocy@cde.org.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322906820213354526, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, authorId=1322906820121079836, language=EN, stringName=Chen-yan GAO, firstName=Chen-yan, middleName=null, lastName=GAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322906820305629215, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, authorId=1322906820121079836, language=CN, stringName=高晨燕, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=国家药品监督管理局药品审评中心,北京 100022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322906819491934222, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, xref=null, ext=[AuthorCompanyExt(id=1322906819504517135, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, companyId=1322906819491934222, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China), AuthorCompanyExt(id=1322906819512905744, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, companyId=1322906819491934222, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=国家药品监督管理局药品审评中心,北京 100022)])])], keywords=[Keyword(id=1322906820410486816, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, language=EN, orderNo=1, keyword=intra-cavity administration), Keyword(id=1322906820494372897, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, language=EN, orderNo=2, keyword=oncolytic virus), Keyword(id=1322906820582453282, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, language=EN, orderNo=3, keyword=cancer), Keyword(id=1322906820649562147, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, language=EN, orderNo=4, keyword=intrapleural), Keyword(id=1322906820708282404, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, language=EN, orderNo=5, keyword=intraperitoneal), Keyword(id=1322906820779585573, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, language=EN, orderNo=6, keyword=clinical study), Keyword(id=1322906820846694438, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, language=CN, orderNo=1, keyword=腔内给药), Keyword(id=1322906820909608999, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, language=CN, orderNo=2, keyword=溶瘤病毒), Keyword(id=1322906820985106472, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, language=CN, orderNo=3, keyword=肿瘤), Keyword(id=1322906821039632425, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, language=CN, orderNo=4, keyword=胸腔注射), Keyword(id=1322906821106741290, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, language=CN, orderNo=5, keyword=腹腔注射), Keyword(id=1322906821182238763, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, language=CN, orderNo=6, keyword=临床研究)], refs=[Reference(id=1322906821287096364, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=GUJAR S, BELL J, DIALLO JS. SnapShot: cancer immunotherapy with oncolytic viruses[J]. Cell, 2019, 176(5): 1240-1240.e1., articleTitle=null, refAbstract=null), Reference(id=1322906821366788141, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=LAN Q, XIA S, WANG Q, et al. Development of oncolytic virotherapy: from genetic modification to combination therapy[J]. Front Med, 2020, 14(2): 160-184., articleTitle=null, refAbstract=null), Reference(id=1322906821446479918, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=MACEDO N, MILLER DM, HAQ R, et al. Clinical landscape of oncolytic virus research in 2020[J]. J Immunother Cancer, 2020, 8(2): e001486., articleTitle=null, refAbstract=null), Reference(id=1322906821513588783, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=CAO GD, HE XB, SUN Q, et al. The oncolytic virus in cancer diagnosis and treatment[J]. Front Oncol, 2020, 10: 1786., articleTitle=null, refAbstract=null), Reference(id=1322906821601669168, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=CHAURASIYA S, FONG Y, WARNER SG. Oncolytic virotherapy for cancer: clinical experience[J]. Biomedicines, 2021, 9(4): 419., articleTitle=null, refAbstract=null), Reference(id=1322906821677166641, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=ABD-AZIZ N, POH CL. Development of oncolytic viruses for cancer therapy[J]. Transl Res, 2021, 237: 98-123., articleTitle=null, refAbstract=null), Reference(id=1322906821765247026, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药品监督管理局药品审评中心. 溶瘤病毒类药物临床试验设计指导原则(试行)[EB/OL]. (2021-02-09). http://www.cde.org.cn/news.do?method=largeInfo&id=20b3679157e4d325., articleTitle=null, refAbstract=null), Reference(id=1322906823430385715, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=LI L, LIU S, HAN D, et al. Delivery and biosafety of oncolytic virotherapy[J]. Front Oncol, 2020, 10: 475., articleTitle=null, refAbstract=null), Reference(id=1322906823510077492, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=KIRN D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials[J]. Expert Opin Biol Ther, 2001, 1(3): 525-538., articleTitle=null, refAbstract=null), Reference(id=1322906823602352181, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=VASEY PA, SHULMAN LN, CAMPOS S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer[J]. J Clin Oncol, 2002, 20(6): 1562-1569., articleTitle=null, refAbstract=null), Reference(id=1322906823682043958, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=杨帆, 卢斌, 胡春燕, 等. 胸腔内注射重组人5型腺病毒治疗晚期肺癌恶性胸腔积液的疗效观察[J]. 实用医学杂志, 2013, 29(17): 2885-2886., articleTitle=null, refAbstract=null), Reference(id=1322906823770124343, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=陈干付, 王和木, 刘合相, 等. 胸腔内注射重组人5型腺病毒治疗晚期肺癌恶性胸腔积液的疗效观察[J]. 蛇志, 2017, 29(4): 457-458, 462., articleTitle=null, refAbstract=null), Reference(id=1322906823946285112, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=KIM KH, DMITRIEV IP, SADDEKNI S, et al. A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer[J]. Gynecol Oncol, 2013, 130(3): 518-524., articleTitle=null, refAbstract=null), Reference(id=1322906824059531321, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=DANSON S, WOLL P, EDWARDS JG, et al. Oncolytic herpesvirus therapy for mesothelioma: a phase Ⅰ/Ⅱa trial of intrapleural administration of HSV1716 (NCT01721018)[J]. Ann Oncol, 2017, 28(s5): v122-v141., articleTitle=null, refAbstract=null), Reference(id=1322906824156000314, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=DANSON SJ, CONNER J, EDWARDS JG, et al. Oncolytic herpesvirus therapy for mesothelioma-A phase Ⅰ/Ⅱa trial of intrapleural administration of HSV1716[J]. Lung Cancer, 2020, 150: 145-151., articleTitle=null, refAbstract=null), Reference(id=1322906824227303483, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=LAUER UM, SCHELL M, BEIL J, et al. Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis[J]. Clin Cancer Res, 2018, 24(18): 4388-4398., articleTitle=null, refAbstract=null), Reference(id=1322906824306995260, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=MINEV BR, LANDER E, FELLER JF, et al. First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells[J]. J Transl Med, 2019, 17(1): 271., articleTitle=null, refAbstract=null), Reference(id=1322906824386687037, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=GALANIS E, HARTMANN LC, CLIBY WA, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer[J]. Cancer Res, 2010, 70(3): 875-882., articleTitle=null, refAbstract=null), Reference(id=1322906824495738942, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=EVANS TR, KEITH WN. Intra-peritoneal administration of genetic therapies: promises and pitfalls[J]. Minerva Ginecol, 2004, 56(6): 529-538., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1322906819491934222, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, xref=null, ext=[AuthorCompanyExt(id=1322906819504517135, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, companyId=1322906819491934222, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China), AuthorCompanyExt(id=1322906819512905744, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, companyId=1322906819491934222, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=国家药品监督管理局药品审评中心,北京 100022)])], figs=null, attaches=null, journal=Journal(id=1235980159023624194, delFlag=0, nameCn=中国新药杂志, nameEn=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, issn=1003-3734, eissn=null, cn=11-2850/R, coden=ZXZHA6, periodic=3, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of New Drugs, journalRemark=null, publicationField=null, createdTime=1772610233314, updatedTime=1788948968376, createdBy=18614031015, updatedBy=13041195026, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=ohPEEN//Vz1tDT3ZBNTp4Q==, picEn=f9WK9bvTM4guTmS/iGhOMg==, jcr=null, cjcr=null, exts=[JournalExt(id=1304509780974924039, language=CN, name=中国新药杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948968404, updatedTime=1788948968404, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1304509781025255688, language=EN, name=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948968416, updatedTime=1788948968416, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1235980733773295621, websiteList=[Website(id=1235982099191222761, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/CN, language=CN, createTime=1772610695884, createBy=18614031015, updateTime=1772610860397, updateBy=18614031015, name=中国新药杂志-中文, tplId=1146099689490845704, title=中国新药杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983918629966444, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=articleTextType, value=kx, createTime=1772611129672, updateTime=1772611129672, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918604800617, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=banner, value=null, createTime=1772611129666, updateTime=1772611129666, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918655132271, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=grayFlag, value=0, createTime=1772611129678, updateTime=1772611129678, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918596412008, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611129664, updateTime=1772611129664, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918667715185, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=minRunFlag, value=0, createTime=1772611129681, updateTime=1772611129681, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918617383531, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic, createTime=1772611129669, updateTime=1772611129669, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918659326576, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=silenceFlag, value=0, createTime=1772611129679, updateTime=1772611129679, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918613189226, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1772611129668, updateTime=1772611129668, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918634160749, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeColor, value=null, createTime=1772611129673, updateTime=1772611129673, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918646743662, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeStyle, value=null, createTime=1772611129676, updateTime=1772611129676, creator=18614031015, updator=18614031015)]), Website(id=1235982099270914542, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/EN, language=EN, createTime=1772610695903, createBy=18614031015, updateTime=1772610875891, updateBy=18614031015, name=中国新药杂志-英文, tplId=1146101810881728533, title=Chinese Journal of New Drugs, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983955829248630, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=articleTextType, value=kx, createTime=1772611138541, updateTime=1772611138541, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955804082803, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=banner, value=null, createTime=1772611138535, updateTime=1772611138535, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955854414457, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=grayFlag, value=0, createTime=1772611138547, updateTime=1772611138547, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955795694194, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611138533, updateTime=1772611138533, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955866997371, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=minRunFlag, value=0, createTime=1772611138550, updateTime=1772611138550, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955820860021, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic, createTime=1772611138539, updateTime=1772611138539, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955862803066, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=silenceFlag, value=0, createTime=1772611138549, updateTime=1772611138549, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955812471412, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1772611138537, updateTime=1772611138537, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955837637239, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeColor, value=null, createTime=1772611138543, updateTime=1772611138543, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955846025848, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeStyle, value=null, createTime=1772611138545, updateTime=1772611138545, creator=18614031015, updator=18614031015)])], journalTitle=中国新药杂志, weixinUrl=null, journalUrl=http://www.newdrug.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of New Drugs, journalPhotoCn=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPhotoEn=f9WK9bvTM4guTmS/iGhOMg==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/Y2021/V30/I19/1814, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/Y2021/V30/I19/1814, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/PDF/Y2021/V30/I19/1814, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/PDF/Y2021/V30/I19/1814, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1634227200000, fullTextJson=null, articleText=null, reference=null)
收藏切换
溶瘤病毒类药物腔内给药临床研究进展
收藏切换
PDF下载
刘晓 , 黄云虹 , 高晨燕
中国新药杂志 | 新药注册与审评技术 2021,30(19): 1814-1818
收起
收藏切换
中国新药杂志 |新药注册与审评技术 2021 , 30 (19) : 1814 -1818
溶瘤病毒类药物腔内给药临床研究进展
全屏
[Author(id=1322906819596791826, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=liux@cde.org.cn, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322906819689066516, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, authorId=1322906819596791826, language=EN, stringName=Xiao LIU, firstName=Xiao, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322906819772952597, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, authorId=1322906819596791826, language=CN, stringName=刘晓, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=国家药品监督管理局药品审评中心,北京 100022, bio={"content":"

刘晓,女,博士,主要从事生物制品临床审评工作。联系电话:(010)85243060,E-mail:。

"}, bioImg=null, bioContent=

刘晓,女,博士,主要从事生物制品临床审评工作。联系电话:(010)85243060,E-mail:。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322906819491934222, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, xref=null, ext=[AuthorCompanyExt(id=1322906819504517135, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, companyId=1322906819491934222, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China), AuthorCompanyExt(id=1322906819512905744, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, companyId=1322906819491934222, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=国家药品监督管理局药品审评中心,北京 100022)])]), Author(id=1322906819852644375, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=huangyh@cde.org.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322906819949113369, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, authorId=1322906819852644375, language=EN, stringName=Yun-hong HUANG, firstName=Yun-hong, middleName=null, lastName=HUANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322906820045582362, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, authorId=1322906819852644375, language=CN, stringName=黄云虹, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=国家药品监督管理局药品审评中心,北京 100022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322906819491934222, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, xref=null, ext=[AuthorCompanyExt(id=1322906819504517135, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, companyId=1322906819491934222, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China), AuthorCompanyExt(id=1322906819512905744, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, companyId=1322906819491934222, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=国家药品监督管理局药品审评中心,北京 100022)])]), Author(id=1322906820121079836, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=gaocy@cde.org.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322906820213354526, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, authorId=1322906820121079836, language=EN, stringName=Chen-yan GAO, firstName=Chen-yan, middleName=null, lastName=GAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322906820305629215, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, authorId=1322906820121079836, language=CN, stringName=高晨燕, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=国家药品监督管理局药品审评中心,北京 100022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322906819491934222, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, xref=null, ext=[AuthorCompanyExt(id=1322906819504517135, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, companyId=1322906819491934222, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China), AuthorCompanyExt(id=1322906819512905744, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322906817239592971, companyId=1322906819491934222, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=国家药品监督管理局药品审评中心,北京 100022)])])]
刘晓 , 黄云虹 , 高晨燕
作者信息
  • 国家药品监督管理局药品审评中心,北京 100022
通讯作者:
黄云虹,女,博士,主要从事生物制品临床审评工作。联系电话:(010)85243080,E-mail:。
高晨燕,女,主任药师,主要从事生物制品临床审评工作。联系电话:(010)85243053,E-mail:。
作者简介:

刘晓,女,博士,主要从事生物制品临床审评工作。联系电话:(010)85243060,E-mail:。

Progress in clinical study of intra-cavity administration of oncolytic virus
Xiao LIU , Yun-hong HUANG , Chen-yan GAO
Affiliations
  • Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China
出版时间: 2021-10-15
文章导航
收藏切换

近年来,越来越多的溶瘤病毒类药物进入临床研究,涉及给药方式主要有瘤内注射、静脉注射、腔内注射、颅内注射和动脉注射等。其中,腔内注射溶瘤病毒目标适应证多为恶性胸腹腔积液、恶性胸膜间皮瘤、胸腹腔部位的肿瘤,由于给药方式本身的特点,溶瘤病毒腔内给药的吸收速度比静脉注射慢,且胸腔注射需要置留管。腔内给药的疗效在不同的溶瘤病毒产品和适应证间差异较大,其中,胸腔注射治疗恶性胸腔积液显现出较好疗效,而腔内注射治疗间皮瘤、卵巢癌疗效尚不明确。由于相关临床研究入组人数均较少,安全性和有效性还需确证性临床试验进一步验证。

腔内给药  /  溶瘤病毒  /  肿瘤  /  胸腔注射  /  腹腔注射  /  临床研究

In recent years, increasing number of oncolytic virus drugs have entered clinical study. Administration approach mainly involves intratumoral, intravenous, intracranial intra-arberial, and so on. Among them, indications for intraperitoneal administration of oncolytic virus mostly include malignant pleural effusion, malignant pleural mesothelioma, and thoracic/abdominal cancer. Due to the inherent characteristics of the administration approach, the absorption of intra-cavity administration is slower than that by intravenous, and the pleural injection requires an indwelling catheter. The efficacy of intraperitoneal administration greatly varies among different oncolytic virus products and indications. Among them, pleural administration for malignant pleural effusion shows good efficacy, while the efficacy of intra-cavity administration for malignant pleural mesothelioma and ovarian cancer is unclear. Due to limited participants in relevant clinical study, the safety and efficacy need further verification by confirming clinical trials.

intra-cavity administration  /  oncolytic virus  /  cancer  /  intrapleural  /  intraperitoneal  /  clinical study
刘晓, 黄云虹, 高晨燕. 溶瘤病毒类药物腔内给药临床研究进展. 中国新药杂志, 2021 , 30 (19) : 1814 -1818 .
Xiao LIU, Yun-hong HUANG, Chen-yan GAO. Progress in clinical study of intra-cavity administration of oncolytic virus[J]. Chinese Journal of New Drugs, 2021 , 30 (19) : 1814 -1818 .

参考文献 引证文献
排序方式:
[1]
GUJAR S, BELL J, DIALLO JS. SnapShot: cancer immunotherapy with oncolytic viruses[J]. Cell, 2019, 176(5): 1240-1240.e1.
[2]
LAN Q, XIA S, WANG Q, et al. Development of oncolytic virotherapy: from genetic modification to combination therapy[J]. Front Med, 2020, 14(2): 160-184.
[3]
MACEDO N, MILLER DM, HAQ R, et al. Clinical landscape of oncolytic virus research in 2020[J]. J Immunother Cancer, 2020, 8(2): e001486.
[4]
CAO GD, HE XB, SUN Q, et al. The oncolytic virus in cancer diagnosis and treatment[J]. Front Oncol, 2020, 10: 1786.
[5]
CHAURASIYA S, FONG Y, WARNER SG. Oncolytic virotherapy for cancer: clinical experience[J]. Biomedicines, 2021, 9(4): 419.
[6]
ABD-AZIZ N, POH CL. Development of oncolytic viruses for cancer therapy[J]. Transl Res, 2021, 237: 98-123.
[7]
国家药品监督管理局药品审评中心. 溶瘤病毒类药物临床试验设计指导原则(试行)[EB/OL]. (2021-02-09). http://www.cde.org.cn/news.do?method=largeInfo&id=20b3679157e4d325.
[8]
LI L, LIU S, HAN D, et al. Delivery and biosafety of oncolytic virotherapy[J]. Front Oncol, 2020, 10: 475.
[9]
KIRN D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials[J]. Expert Opin Biol Ther, 2001, 1(3): 525-538.
[10]
VASEY PA, SHULMAN LN, CAMPOS S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer[J]. J Clin Oncol, 2002, 20(6): 1562-1569.
[11]
杨帆, 卢斌, 胡春燕, 等. 胸腔内注射重组人5型腺病毒治疗晚期肺癌恶性胸腔积液的疗效观察[J]. 实用医学杂志, 2013, 29(17): 2885-2886.
[12]
陈干付, 王和木, 刘合相, 等. 胸腔内注射重组人5型腺病毒治疗晚期肺癌恶性胸腔积液的疗效观察[J]. 蛇志, 2017, 29(4): 457-458, 462.
[13]
KIM KH, DMITRIEV IP, SADDEKNI S, et al. A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer[J]. Gynecol Oncol, 2013, 130(3): 518-524.
[14]
DANSON S, WOLL P, EDWARDS JG, et al. Oncolytic herpesvirus therapy for mesothelioma: a phase Ⅰ/Ⅱa trial of intrapleural administration of HSV1716 (NCT01721018)[J]. Ann Oncol, 2017, 28(s5): v122-v141.
[15]
DANSON SJ, CONNER J, EDWARDS JG, et al. Oncolytic herpesvirus therapy for mesothelioma-A phase Ⅰ/Ⅱa trial of intrapleural administration of HSV1716[J]. Lung Cancer, 2020, 150: 145-151.
[16]
LAUER UM, SCHELL M, BEIL J, et al. Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis[J]. Clin Cancer Res, 2018, 24(18): 4388-4398.
[17]
MINEV BR, LANDER E, FELLER JF, et al. First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells[J]. J Transl Med, 2019, 17(1): 271.
[18]
GALANIS E, HARTMANN LC, CLIBY WA, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer[J]. Cancer Res, 2010, 70(3): 875-882.
[19]
EVANS TR, KEITH WN. Intra-peritoneal administration of genetic therapies: promises and pitfalls[J]. Minerva Ginecol, 2004, 56(6): 529-538.
2021年第30卷第19期
PDF下载
4
0
引用本文
BibTeX
文章信息
  • 首发时间:2026-10-30
  • 出版时间:2021-10-15
补充材料
相关文章
文章信息
作者
出版历史
  • 录用日期:2021-08-10
基金
作者信息
    国家药品监督管理局药品审评中心,北京 100022

通讯作者:

黄云虹,女,博士,主要从事生物制品临床审评工作。联系电话:(010)85243080,E-mail:。
高晨燕,女,主任药师,主要从事生物制品临床审评工作。联系电话:(010)85243053,E-mail:。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322906817239592971
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏